Dr. Prigione received a M.D. from the University of Milan in 2002 and a Ph.D. from the San Raffaele Institute of Milan in 2008. During his Ph.D., Dr. Prigione worked on neurological diseases at the University of Milan-Bicocca and on mitochondrial disorders at the University of California in Davis, USA. As postdoctoral scientist at the Max Planck Institute for Molecular Genetics in Berlin, Dr. Prigione described for the first time the reconfiguration occurring to mitochondria during the reprogramming of human fibroblasts to iPSCs.
The focus of the Prigione lab is now the application of iPSCs in modeling and treatment discovery of neurological diseases with mitochondrial impairment. His latest work was published in Cell Stem Cell in January 2017 and demonstrated the use of iPSC-derived neural cells for drug discovery of neurological disorders caused by mitochondrial DNA mutations.